CAM2038 includes two long-acting subcutaneous buprenorphine products for maintenance treatment of opiod dependence, intended for administration once weekly (q1w) and once monthly (q4w). The products, based on Camurus’ proprietary FluidCrystal® injection depot technology, are being developed to address several shortcomings of currently available drugs, for instance poor compliance, extensive misuse and diversion, and frequent relapse to abuse.
CAM2038 combines the known and well documented active substance buprenorphine with Camurus’ proprietary FluidCrystal® injection depot technology. Because of the long-acting effect, CAM2038 needs to be administered only 12 or 52 times per year, which reduces the burden of daily administration as is the case with current medications (often health care personnel monitored administration, which is time consuming and costly for patients and society). CAM2038 will be administered in a controlled setting by healtcare personnel as a convenient subcutaneous injection, which cannot be misused, abused, or diverted to the illegal market.
CAM2038 will be available in several doses for weekly and monthly administration. This flexibility was developed to enable the product to be used during all phases of opioid addiction treatment, from treatment induction to stabilization and long-term maintenance therapy. The dose flexibility is also important to meet the patients’ individual needs, depending on treatment phase, abuse history, and other factors. CAM2038 will be provided in prefilled syringes with a needle stick protection device. The products are small volume subcutaneous injections without need for reconstitution before use.
CAM2038 key properties
- Reduced dosing frequency
- Protection against misuse, abuse, and diversion
- No risk of pediatric exposure
- Flexible doses for individualized treatment
- Blockage of illegal opioids